Quidelortho Corp

Health Care
Biotechnology: In Vitro & In Vivo Diagnostic Substances
www.quidelortho.com

Earnings Score
Moat Score
Safety Score

Market Cap $1.74B
PE -1
Debt $2.83B
Cash $98.50M
EV $4.47B
FCF -$112.10M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$2.05B
EBIT	-$1.96B
ROE	-69%
ROA	-31%
FCF	-$112.10M
Equity	$2.98B
Growth Stability	-495%
PE	-0.85
PEG	0.07
PB	0.58
P/FCF	-15.55
P/S	0.63
Price/Cash	0.06
Debt/Equity	0.95
Debt/FCF	-25.25
Net Margins	-74%
Gross Margins	46%
Op. Margins	-70%
Earnings CAGR	-12%
Sales Growth YoY	-5%
Sales Growth QoQ	-3%
Sales CAGR	7%
FCF CAGR	-9%
Equity CAGR	29%
Earnings Stability	-0.8
Earnings Growth YoY	-3K%
Earnings Growth QoQ	796%

Earnings CAGR 5Y	-12%
Sales CAGR 5Y	7%
FCF CAGR 5Y	-9%
Equity CAGR 5Y	29%
Earnings CAGR 3Y	-3%
Sales CAGR 3Y	-3%
FCF CAGR 3Y	-18%
Equity CAGR 3Y	-9%
Market Cap	$1.74B
Revenue	$2.78B
Assets	$6.42B
Total Debt	$2.83B
Cash	$98.50M
Shares Outstanding	67.19M
EV	4.47B
Earnings Score	6%
Moat Score	1%
Safety Score	37%
Final Score	15%
Working Capital	220.1M
Current Ratio	1.22
Gross Profit	$1.29B
Shares Growth 3y	16%
Equity Growth QoQ	-6%
Equity Growth YoY	-40%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.

SEC Filings

Direct access to Quidelortho Corp (QDEL) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-K Dec 29
- 10-Q Sep 29
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Oct 01
- 10-Q Jul 02
- 10-Q Apr 02
- 10-K Jan 01
2022
- 10-Q Oct 02
- 10-Q Jul 03

Sector Comparison

How does Quidelortho Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Quidelortho Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -12%

Stability -80%

loading chart...

Quidelortho Corp Discounted Cash Flow

Fully customizable DCF calculator online for Quidelortho Corp.

Years

Calculation mode

= -$634M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$112M	-$102M	-$93M	-$85M	-$78M	-$71M	-$65M	-$59M	-$54M	-$49M	-$45M	-$449M
DCF		-$93M	-$77M	-$64M	-$53M	-$44M	-$37M	-$30M	-$25M	-$21M	-$17M	-$173M
Value	-$634M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	01/2021	01/2022	12/2022	12/2023	12/2024	TTM
Net Margins	49%	41%	17%	-0%	-74%	-74%
ROA	-	37%	10%	2%	-31%	-31%
ROE	-	36%	11%	-0%	-69%	-69%

Bad Net Margins (-73.74%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	01/2021	01/2022	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	0	3.84	36.14	-25.25	-25.25
Debt over Equity	-	0	0.58	0.51	0.95	0.95
Growth Stability	-	-	-	-1%	-495%	-495%

Good Debt/FCF ratio (-25.25)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.95)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-495%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	01/2021	01/2022	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	2%	92%	-8%	-7%	7%
Earnings YoY growth	-	-13%	-22%	-102%	20K%	-12%
Equity YoY growth	-	45%	156%	1%	-40%	29%
FCF YoY growth	-	-9%	45%	-90%	-258%	-9%